J&J’s Ebola Vaccine Produces Two-Year Immune Response
Johnson & Johnson (J&J) reported that its Ebola vaccine generated antibody immune responses in adults and children that lasted for two years.
Data from two studies published in The Lancet Infectious Diseases demonstrated that the vaccine regimen — Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) — was well-tolerated, induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98 percent of all participants, and that participants’ immune response stayed strong for at least 24 months. There were no significant safety issues.
The data also showed that booster vaccination with Zabdeno, administered to adults two years after the initial vaccination, induced a strong immune response within seven days.
J&J said the findings support the potential prophylactic use of the vaccine regimen, which was developed by its subsidiary Janssen in collaboration with Bavarian Nordic and was granted marketing authorization by the European Commission in July 2020 and prequalification from the World Health Organization in April.